https://pharmatrophix.com/pr_funding_investor/new-study-in-nature-medicine-shows-novel-neuroprotective-drug-candidate-meets-primary-endpoint-in-patients-with-mild-to-moderate-alzheimers-disease/ 2026-05-04T14:55:24+00:00 https://pharmatrophix.com/pr_funding_investor/targeting-endogenous-mechanisms-of-brain-resilience-for-the-treatment-and-prevention-of-alzheimers-disease/ 2026-05-04T15:53:15+00:00 https://pharmatrophix.com/pr_funding_investor/p75-neurotrophin-receptor-modulation-in-mild-to-moderate-alzheimer-disease-a-randomized-placebo-controlled-phase-2a-trial/ 2026-05-04T15:53:53+00:00